Episode Details

Researchers compared nearly 53,000 Wegovy patients to the same number of closely matched users of other weight-loss drugs. 

研究人员将近53,000名Wegovy患者与其他减肥药物的密切匹配使用者进行了比较。

They found that during the first six months of use, first-time suicidal thoughts were reported by 0.11 percent of Wegovy users. That is compared to 0.43 percent of users of other drugs that do not belong to the same class as semaglutide. 

他们发现，在使用的前六个月中，有0.11％的Wegovy用户报告了首次自杀念头。 相比之下，有0.43％的其他药物的用户与semaglutide不属于同一类。

 
After taking other risk factors into consideration, the risk of first-time suicidal thoughts was 73 percent lower with Wegovy, the researchers said. 

研究人员说，在考虑了其他风险因素之后，Wegovy首次自杀念头的风险降低了73％。 

No patient in the Wegovy group reported a suicide attempt, compared to 14 users of the other drugs, the report said. 

报告说，Wegovy组中没有患者报告自杀企图，而其他药物的14种使用者。 

Among patients with a history of suicidal thoughts, the risk of recurring suicidal thoughts was 56 percent lower with Wegovy than other weight-loss medicines.

在有自杀思想史的患者中，与其他减肥药物相比，Wegovy的反复自杀思想的风险低56％。 

Similar patterns were seen for use of Ozempic compared with other diabetes drugs. 

与其他糖尿病药物相比，观察到使用Ozempic的类似模式。 

The findings were consistent no matter the patients’ sex, age, or ethnicity for both semaglutide types, the researchers found. 

研究人员发现，无论患者两种类型的患者的性别，年龄或种族如何，这些发现都是一致